CHICAGO--(BUSINESS WIRE)--SIA, a privately-held medical device manufacturer, today announced the appointment of Jason O’Hearn as Chief Commercial Officer.
Mr. O’Hearn brings to SIA over 25 years of experience and a proven track record of developing and leading successful commercial organizations for aesthetic and regenerative medical devices. Mr. O’Hearn previously held executive roles of increasing responsibility within Sientra (SIEN) and Mentor Corporation WW LLC, a division of Johnson & Johnson (JNJ). He has led global sales – including both the introduction of new brands and the growth of market-leading devices – within the reconstructive and plastic surgery market.
“Jason has demonstrated the ability to create value and accumulate market share in the highly-competitive aesthetics market,” said Ryan Egeland, MD, PhD, SIA investor and Board Director, “He brings a trusted name and a wealth of diverse but sector-specific expertise to the SIA management team during this important commercial transition for the company.”
Prior to joining SIA, Mr. O’Hearn was General Manager and VP of Aesthetics for Sientra Inc (SIEN), responsible for its entire portfolio of breast implants, expanders, and scar treatments. He was promoted to that position after joining the company at the pre-revenue stage and launching multiple brands to achieve a peak market share of 17% within three years of launch. His business development expertise is grounded by direct customer interaction and sales early in his career with Mentor, where he went on to lead global sales for a business unit with $250M annual revenue before joining Sientra. Mr. O’Hearn holds a BA in Business Management and a minor in Finance from San Diego State University.
“I am very happy to join the talented and dedicated team at SIA,” said Mr. O’Hearn regarding his new role, “Our flagship product, DuraSorb®, will transform the use of soft tissue support to provide patients with long-lasting and predictable outcomes.”
About Surgical Innovation Associates (SIA)
SIA is committed to bringing better outcomes to patients and lowering systemic costs through innovation “for surgeons, by surgeons” in reconstructive and cosmetic surgery. Founded in Chicago in 2016, SIA has since advanced its patented DuraSorb® product line from ideation through FDA 510k clearance and into the operating room, where its nationwide post-market registry has favorable clinical outcomes in a variety of indications at up to 14 months of follow-up. The company plans to pursue development and clinical investigation of additional products for breast reconstruction and facial aesthetics, among others.
Learn more at SIA.health.
